Actively Recruiting
To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients
Led by Henan Cancer Hospital · Updated on 2024-09-20
300
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
For newly diagnosed ISLNM breast cancer, on the basis of effective treatment of the new auxiliary system, the optimal local treatment of the supraclavicular region remains controversial. Although guidelines such as NCCN recommend simple clavicular radiation therapy, there are studies suggesting that supraclavicular lymph node dissection can improve prognosis, and many hospitals in China are still accustomed to performing supraclavicular lymph node dissection. Therefore, ipsilateral supraclavicular lymph node dissection is the first time to diagnose ipsilateral supraclavicular lymph node metastasis of breast cancer. The effectiveness and safety of (stage IIIc) treatment still require prospective research to confirm.This project is a prospective, multicenter, non-interference real world study. In the real world study, the investigators evaluated the efficacy and safety of ipsilateral supraclavicular lymph node dissection in the treatment of initially diagnosed ipsilateral supraclavicular lymph node metastasis breast cancer patients.
CONDITIONS
Official Title
To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients aged 80 years old or younger
- ECOG performance status score of 0 or 1
- Histologically diagnosed invasive breast cancer with known ER, PR, HER2, and KI67 status
- Pathological confirmation of ipsilateral supraclavicular lymph node metastasis by cytology or histopathology
- Estimated survival time greater than three months
- No obvious contraindications for surgery or radiotherapy
- Ability to comply with the study protocol as judged by the researcher
- Participation in other clinical trials allowed if not affecting this study
- Voluntary participation with signed informed consent
You will not qualify if you...
- Stage IV (metastatic) breast cancer
- Bilateral breast cancer
- Prior radiotherapy or surgical treatment for ipsilateral supraclavicular metastatic lymph nodes (excluding local puncture)
- History of breast cancer or other malignant tumors except cured cervical carcinoma in situ or skin basal/squamous cell carcinoma
- Severe primary diseases such as cardiovascular, cerebrovascular, liver, or kidney conditions that hinder surgery or radiotherapy
- History of immunodeficiency, including positive HIV test or organ transplantation
- Severe comorbidities or other conditions interfering with planned treatment or judged unsuitable by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henan Cancer Hospital
Zhengzhou, Henan, China, 450000
Actively Recruiting
Research Team
X
xiuchun Chen
CONTACT
M
Minhao Lv
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here